Aspira Women’s Health Appoints Dr. Winfred Parnell to its Board of Directors
June 05, 2023 08:00 ET AUSTIN, Texas, June 05, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Dr. Winfred Parnell as a new independent director on the Aspira Board of Directors, effective…
Aspira Women’s Health Regained Compliance with Nasdaq’s Minimum Bid Price Requirement
June 02, 2023 08:00 ET AUSTIN, Texas, June 02, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, announced today that it has received notification from the Listing Qualifications Department (“the Staff”) of the Nasdaq Stock Market (“Nasdaq”)…
Aspira Women’s Health Announces the Publication of Three Abstracts by the American Society of Clinical Oncology (ASCO) Supporting the Clinical Utility of OvaSuite(SM) Ovarian Cancer Risk Assessment Tests
May 31, 2023 08:00 ET AUSTIN, Texas, May 31, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, announced the online publication of three abstracts supporting the clinical utility of OvaWatchSM at the 2023 American Society of Clinical Oncology…
Aspira Women’s Health to Participate at William Blair’s 43rd Annual Growth Stock Conference
May 30, 2023 08:00 ET AUSTIN, Texas, May 30, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health, Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the company will participate in William Blair’s 43rd Annual Growth Stock Conference taking place in Chicago, Illinois…
Aspira Women’s Health to Present at the 2023 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Conference
May 19, 2023 08:00 ET AUSTIN, Texas, May 19, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it would present at the upcoming 2023 American College of Obstetricians and Gynecologists (“ACOG”) Annual Clinical & Scientific…
Aspira Women’s Health Names Torsten Hombeck as Chief Financial Officer
May 16, 2023 16:05 ET AUSTIN, Texas, May 16, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has appointed Torsten Hombeck, Ph.D., as Chief Financial Officer, replacing interim CFO Marlene McLennan. Dr. Hombeck brings…
Aspira Women’s Health to Host Investor Day on OvaWatch(SM) and EndoCheck™ Market Opportunities on May 23, 2023
May 15, 2023 16:05 ET AUSTIN, Texas, May 15, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it will host a virtual Investor Day on Tuesday, May 23, 2023 at 1:00pm ET. Click here to…
Aspira Women’s Health Announces 1-for-15 Reverse Stock Split
May 11, 2023 12:33 ET AUSTIN, Texas, May 11, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic, tools, today announced a 1-for-15 reverse stock split of its outstanding common stock, effective at 12:01 am Eastern time on May…
Aspira Women’s Health Signs an Exclusive Licensing Agreement with Dana Farber Cancer Institute for the Development of microRNA-based Ovarian Cancer Test
New blood-based test could use microRNA alone or in combination with other biomarkers for earlier diagnosis of ovarian cancer May 11, 2023 08:00 ET AUSTIN, Texas, May 11, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today announced it has signed an exclusive…
Aspira Women’s Health® Reports First Quarter 2023 Financial Results
May 11, 2023 16:01 ET First Quarter total product revenue of $2.3 million, an increase of 26% year-over-year First Quarter OvaSuite volume of 6,259 units, an increase of 29% year-over-year First Quarter cash used in operations of $5.7 million, a decrease of 44% year-over-year Conference Call and Webcast scheduled for today 4:30 pm Eastern Time…
Aspira Women’s Health Appoints Three New Members to its Board of Directors
May 09, 2023 16:07 ET AUSTIN, Texas, May 09, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it the appointment of three new independent directors: Stefanie Cavanaugh, Jannie Herchuck, and Lynn O’Connor Vos. “We are…
Aspira Women’s Health Announces Preliminary First Quarter 2023 OvaSuite Volume Increase of 29% and Plans to Announce Full Earnings Results on May 11, 2023
April 27, 2023 16:05 ET Preliminary first quarter 2023 volume was 6,259 tests, an increase of 29% compared to last year, the highest volume quarter in the company’s history Management to host its first quarter earnings conference call on Thursday, May 11 at 4:30 pm AUSTIN, Texas, April 27, 2023 (GLOBE NEWSWIRE) — Aspira Women’s…
Aspira Women’s Health Reports Fourth Quarter and Full Year 2022 Financial Results
March 22, 2023 16:05 ET 2022 total revenue of $8.2 million, an increase of 20% year-over-year 2022 total OvaSuiteSM volume of 21,423 units, an increase 23% year-over-year Fourth quarter 2022 cash utilization of $7.1 million Conference Call and Webcast scheduled for today at 4:30 pm Eastern Time AUSTIN, Texas, March 22, 2023 (GLOBE NEWSWIRE) —…
Aspira Women’s Health to Announce Year End 2022 Financial Results and Host Conference Call on March 22, 2023
March 03, 2023 08:38 ET AUSTIN, Texas, March 03, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today announced that the company will report its financial results for the year ended December 31, 2022 after the market closes on Wednesday, March 22, 2023.…
Aspira Women’s Health Announces National Payer Coverage for OvaWatch
First National Payer to Cover OvaWatch March 03, 2023 08:00 ET AUSTIN, Texas, March 03, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today announced that one of the nation’s top national health insurance companies with over 80 million lives worldwide has agreed…
Aspira Women’s Health Announces Preliminary Fourth Quarter 2022 Volume, Preliminary Results in Line with Cash Utilization Guidance, and Other Highlights
January 09, 2023 16:05 ET Preliminary testing volume during the fourth quarter of 2022 was 5,643, an increase of 18 % compared to the fourth quarter of 2021 Preliminary results consistent with previously provided cash utilization guidance for the fourth quarter and full year of 2022 Further reduced staff to achieve anticipated year-over-year salary cost…
Aspira Women’s Health Announces Publication of Real-World Data Validating Use of OvaWatch for the Management of Adnexal Masses
January 06, 2023 08:00 ET Provides clinical validation for the use of OvaWatchSM in the assessment of ovarian cancer risk for suspected benign or indeterminate adnexal masses Paper published in the peer-reviewed journal, Frontiers in Medicine AUSTIN, Texas, Jan. 06, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company…
Aspira Women’s Health Announces Three Reimbursement Milestones that Improve Patient Access to its OvaSuite SM Testing Portfolio
December 27, 2022 08:00 ET Expanded Medicare coverage for multi-marker testing, including Ova1Plus® and OvaWatchSM, through the 2023 Omnibus Spending Bill Granted a new PLA Code for OvaWatch by the American Medical Association Expanded Medicaid coverage adding another 5 states: Virginia, Alabama, Maine, Pennsylvania, and Rhode Island AUSTIN, Texas, Dec. 27, 2022 (GLOBE NEWSWIRE) —…
Aspira Women’s Health Announces the Commercial Launch of OvaWatch(SM)
November 29, 2022 16:01 ET AUSTIN, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, announced the commercial launch of OvaWatchSM, a new non-invasive blood-based test for the assessment of ovarian cancer risk in women with adnexal masses. OvaWatch is part of…
Aspira Women’s Health Reports Third Quarter 2022 Financial Results
November 10, 2022 07:00 ET Increased year-over-year product revenue by 26% to $2.0 million and year-over-year product volume by 29% to 5,524 units Reconfirmed fourth quarter launch of OvaWatch ovarian cancer risk assessment and announced rebranding of the ovarian cancer product portfolio as OvaSuite Executed and fully funded a sponsored research agreement with Harvard’s Dana…
Aspira Women’s Health to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10
November 01, 2022 08:00 ET AUSTIN, Texas, Nov. 01, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that the company will report its financial results for the third quarter ended September 30, 2022 before the market open on Thursday, November 10, 2022. Management will also host…
Aspira Women’s Health to Participate at the Upcoming MicroCap Rodeo Windy City Roundup 2022
October 06, 2022 16:05 ET AUSTIN, Texas, Oct. 06, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that management will present and be available for 1×1 meetings at the MicroCap Rodeo Presents Windy City Roundup 2022 conference taking place in-person on October 12-13, 2022 in Chicago,…
Aspira Women’s Health Announces Formal Launch of Co-Marketing and Distribution Collaboration with BioReference
OVA1Plus® now available to an expanded network of physicians, supporting patients nationwide October 05, 2022 08:00 ET AUSTIN, Texas, Oct. 05, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced the formal launch of its co-marketing and distribution collaboration with BioReference®, an OPKO…
Aspira Women’s Health Announces Publication of its Second-Generation MultiVariate Index Assay, OVERA®, in the Detection of Cancer in Filipino Women
Data demonstrates the accuracy of Aspira’s multivariate assessment test OVERA in a non-White population and concludes use of OVERA to be better than CA-125 in detecting early-stage cancer in women with a pelvic mass September 12, 2022 16:28 ET AUSTIN, Texas, Sept. 12, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based…
Aspira Women’s Health Inc. Announces Pricing of $9.0 Million Public Offering
August 23, 2022 08:00 ET AUSTIN, Texas, Aug. 23, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (Nasdaq: AWH) (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced the pricing of the previously announced underwritten public offering of 12,000,000 shares of its common stock and warrants to purchase an aggregate of…